CN1198839C - 作为凝血酶抑制剂的新的二肽脒类 - Google Patents
作为凝血酶抑制剂的新的二肽脒类 Download PDFInfo
- Publication number
- CN1198839C CN1198839C CNB961919671A CN96191967A CN1198839C CN 1198839 C CN1198839 C CN 1198839C CN B961919671 A CNB961919671 A CN B961919671A CN 96191967 A CN96191967 A CN 96191967A CN 1198839 C CN1198839 C CN 1198839C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- phenyl
- pro
- benzyl
- boc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19505484 | 1995-02-17 | ||
| DE19505484.9 | 1995-02-17 | ||
| DE19506611 | 1995-02-24 | ||
| DE19506611.1 | 1995-02-24 | ||
| DE19507455.6 | 1995-03-03 | ||
| DE19507455 | 1995-03-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1175953A CN1175953A (zh) | 1998-03-11 |
| CN1198839C true CN1198839C (zh) | 2005-04-27 |
Family
ID=27214848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB961919671A Expired - Fee Related CN1198839C (zh) | 1995-02-17 | 1996-02-12 | 作为凝血酶抑制剂的新的二肽脒类 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6030972A (enExample) |
| EP (1) | EP0873356A1 (enExample) |
| JP (1) | JPH11500120A (enExample) |
| KR (1) | KR100388185B1 (enExample) |
| CN (1) | CN1198839C (enExample) |
| AR (1) | AR002277A1 (enExample) |
| AU (1) | AU708001B2 (enExample) |
| BG (1) | BG63697B1 (enExample) |
| BR (1) | BR9607582A (enExample) |
| CA (1) | CA2211109A1 (enExample) |
| CZ (1) | CZ245797A3 (enExample) |
| EA (1) | EA199700186A1 (enExample) |
| FI (1) | FI973360A0 (enExample) |
| HR (1) | HRP960075B1 (enExample) |
| HU (1) | HUP9800263A3 (enExample) |
| IL (1) | IL117165A0 (enExample) |
| MX (1) | MX9706069A (enExample) |
| MY (1) | MY132115A (enExample) |
| NO (1) | NO973764L (enExample) |
| NZ (1) | NZ302649A (enExample) |
| PL (1) | PL321759A1 (enExample) |
| SI (1) | SI9620037A (enExample) |
| SK (1) | SK104697A3 (enExample) |
| TR (1) | TR199700803T1 (enExample) |
| TW (1) | TW450968B (enExample) |
| WO (1) | WO1996025426A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
| US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| CZ245797A3 (cs) * | 1995-02-17 | 1998-06-17 | Basf Aktiengesellschaft | Derivát amidinu dipeptidu jako inhibitor thrombinu |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
| SA96170106A (ar) * | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
| TW541316B (en) * | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
| AU3496297A (en) * | 1996-06-25 | 1998-01-14 | Eli Lilly And Company | Anticoagulant agents |
| EP1110968B1 (en) * | 1996-06-25 | 2003-10-01 | Eli Lilly & Company | Intermediate for the preparation of Thrombininhibitors as anticoagulant agents |
| US6200967B1 (en) | 1996-06-25 | 2001-03-13 | Eli Lilly And Company | Anticoagulant agents |
| SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
| DE19632772A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| DE19632773A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
| AR013084A1 (es) * | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
| SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
| WO1999037611A1 (de) * | 1998-01-26 | 1999-07-29 | Basf Aktiengesellschaft | Heterocyclische amidine als kallikrein protease inhibitoren |
| WO1999055355A1 (en) | 1998-04-24 | 1999-11-04 | 3-Dimensional Pharmaceuticals, Inc. | Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors |
| SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
| US6486193B2 (en) | 1998-12-31 | 2002-11-26 | Aventis Pharmaceuticals Inc. | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases |
| IL143987A (en) | 1999-01-13 | 2005-12-18 | Astrazeneca Ab | Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin |
| WO2000061577A1 (de) * | 1999-04-09 | 2000-10-19 | Basf Aktiengesellschaft | Prodrugs von thrombininhibitoren |
| WO2000061608A2 (de) | 1999-04-09 | 2000-10-19 | Basf Aktiengesellschaft | Niedermolekulare inhibitoren von komplementproteasen |
| AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| EP1054017B1 (de) * | 1999-05-10 | 2004-10-13 | Abbott GmbH & Co. KG | Salze von Thrombininhibitoren |
| DE19921346A1 (de) | 1999-05-10 | 2000-11-16 | Basf Ag | Sprühtrocknung von Thrombininhibitoren |
| SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
| DE10029015A1 (de) * | 2000-06-15 | 2001-12-20 | Curacyte Ag | Hemmstoffe für den Gerinnungsfaktor Xa |
| US6433186B1 (en) | 2000-08-16 | 2002-08-13 | Astrazeneca Ab | Amidino derivatives and their use as thormbin inhibitors |
| DE10049937A1 (de) * | 2000-10-06 | 2002-04-11 | Knoll Ag | Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten |
| RU2300521C2 (ru) * | 2000-12-01 | 2007-06-10 | Астразенека Аб | Новые производные миндальной кислоты и их применение в качестве ингибиторов тромбина |
| AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
| DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
| US6774110B2 (en) * | 2001-03-19 | 2004-08-10 | Lg Life Sciences Ltd. | Orally available peptidic thrombin inhibitors |
| AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| DE10210590A1 (de) * | 2002-03-11 | 2003-10-02 | Curacyte Ag | Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
| JP4898091B2 (ja) | 2002-03-11 | 2012-03-14 | ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー | ウロキナーゼの阻害剤、それらの製造および使用 |
| WO2003086288A2 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
| SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| SE0201659D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| RU2228930C1 (ru) * | 2003-05-20 | 2004-05-20 | ООО "Исследовательский институт химического разнообразия" | Замещенные 3-пиридилметиламины и фокусированная библиотека |
| US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| DE10342108A1 (de) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
| EP1682120A4 (en) * | 2003-11-04 | 2009-05-27 | Merck & Co Inc | CAPACITATED PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDAS IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| US7795205B2 (en) | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
| EP1747206A1 (en) | 2004-04-29 | 2007-01-31 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
| JP4561197B2 (ja) * | 2004-06-28 | 2010-10-13 | 宇部興産株式会社 | ５−（４−テトラヒドロピラニル）ヒダントインの製法及びその中間体 |
| JP4572618B2 (ja) * | 2004-08-04 | 2010-11-04 | 宇部興産株式会社 | ４−テトラヒドロピラニルグリシンの製法 |
| US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
| US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
| CN102464701B (zh) * | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2113982A1 (de) * | 1970-03-25 | 1971-10-14 | Sumitomo Chemical Co | Verfahren zur Herstellung von Benzodiazepinen |
| DE2059922A1 (de) * | 1970-12-05 | 1972-06-15 | Boehringer Mannheim Gmbh | Neue N(6)-Aralkyl-adenosin-Derivate und Verfahren zur Herstellung derselben |
| HU178398B (en) * | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
| GB8305985D0 (en) * | 1983-03-04 | 1983-04-07 | Szelke M | Enzyme inhibition |
| HU192646B (en) * | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
| AU600226B2 (en) * | 1985-02-04 | 1990-08-09 | Merrell Pharmaceuticals Inc. | Novel peptidase inhibitors |
| US5187157A (en) * | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0362002B1 (en) * | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
| ZA897514B (en) * | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
| CA2021660A1 (en) * | 1989-07-26 | 1991-01-27 | Philippe Bey | Peptidase inhibitors |
| GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
| GB9024129D0 (en) * | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
| EP0503203A1 (en) * | 1991-03-15 | 1992-09-16 | Merrell Dow Pharmaceuticals Inc. | Novel thrombin inhibitors |
| CA2075154A1 (en) * | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| SE9102462D0 (sv) * | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
| CZ333492A3 (en) * | 1991-11-12 | 1993-09-15 | Lilly Co Eli | Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised |
| SE9103612D0 (sv) * | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
| CA2129339C (en) * | 1992-02-14 | 2002-09-10 | George P. Vlasuk | Inhibitors of thrombosis |
| DE69314478T2 (de) * | 1992-03-04 | 1999-02-11 | Gyogyszerkutato Intezet Kft., Budapest | Neuartige antikoagulierende peptidderivate und arzneimittel die solche enthalten so wie entsprechendes herstellungsverfahren |
| FR2695562B1 (fr) * | 1992-09-11 | 1994-10-14 | Synthelabo | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique. |
| US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
| US5346129A (en) * | 1993-05-17 | 1994-09-13 | Honeywell Inc. | Indoor climate controller system adjusting both dry-bulb temperature and wet-bulb or dew point temperature in the enclosure |
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| US5780631A (en) * | 1993-06-03 | 1998-07-14 | Astra Aktiebolag | Starting materials in the synthesis of thrombin and kininogenase inhibitors |
| AU1025795A (en) * | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
| US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
| US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| US5849510A (en) * | 1994-04-26 | 1998-12-15 | Selectide Corporation | Factor Xa inhibitors |
| EP1384725A3 (en) | 1994-04-26 | 2007-02-21 | Aventis Pharmaceuticals Inc. | Factor Xa inhibitors |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| DE4421052A1 (de) * | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
| CZ245797A3 (cs) * | 1995-02-17 | 1998-06-17 | Basf Aktiengesellschaft | Derivát amidinu dipeptidu jako inhibitor thrombinu |
| US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
-
1996
- 1996-02-12 CZ CZ972457A patent/CZ245797A3/cs unknown
- 1996-02-12 JP JP8524648A patent/JPH11500120A/ja not_active Ceased
- 1996-02-12 NZ NZ302649A patent/NZ302649A/xx unknown
- 1996-02-12 AU AU48751/96A patent/AU708001B2/en not_active Ceased
- 1996-02-12 MX MX9706069A patent/MX9706069A/es unknown
- 1996-02-12 CN CNB961919671A patent/CN1198839C/zh not_active Expired - Fee Related
- 1996-02-12 FI FI973360A patent/FI973360A0/fi not_active IP Right Cessation
- 1996-02-12 PL PL96321759A patent/PL321759A1/xx unknown
- 1996-02-12 SK SK1046-97A patent/SK104697A3/sk unknown
- 1996-02-12 US US08/894,252 patent/US6030972A/en not_active Expired - Lifetime
- 1996-02-12 BR BR9607582A patent/BR9607582A/pt not_active IP Right Cessation
- 1996-02-12 HU HU9800263A patent/HUP9800263A3/hu unknown
- 1996-02-12 KR KR1019970705682A patent/KR100388185B1/ko not_active Expired - Fee Related
- 1996-02-12 WO PCT/EP1996/000582 patent/WO1996025426A1/de not_active Ceased
- 1996-02-12 EA EA199700186A patent/EA199700186A1/ru unknown
- 1996-02-12 SI SI9620037A patent/SI9620037A/sl not_active IP Right Cessation
- 1996-02-12 EP EP96904759A patent/EP0873356A1/de not_active Withdrawn
- 1996-02-12 CA CA002211109A patent/CA2211109A1/en not_active Abandoned
- 1996-02-12 TR TR97/00803T patent/TR199700803T1/xx unknown
- 1996-02-15 HR HR960075A patent/HRP960075B1/xx not_active IP Right Cessation
- 1996-02-15 AR ARP960101389A patent/AR002277A1/es not_active Application Discontinuation
- 1996-02-16 TW TW085102085A patent/TW450968B/zh not_active IP Right Cessation
- 1996-02-17 MY MYPI96000644A patent/MY132115A/en unknown
- 1996-02-18 IL IL11716596A patent/IL117165A0/xx unknown
-
1997
- 1997-08-15 BG BG101835A patent/BG63697B1/bg unknown
- 1997-08-15 NO NO973764A patent/NO973764L/no not_active Application Discontinuation
-
1999
- 1999-10-08 US US09/414,681 patent/US6444817B1/en not_active Expired - Lifetime
-
2002
- 2002-03-19 US US10/100,099 patent/US6900319B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1198839C (zh) | 作为凝血酶抑制剂的新的二肽脒类 | |
| CN1189476C (zh) | 新的凝血酶抑制剂及其制备方法和用途 | |
| CN1298703C (zh) | 氰基吡咯烷衍生物 | |
| CN1178905C (zh) | 新的肽衍生物 | |
| CN1134264C (zh) | 抗血栓形成剂 | |
| CN1152048C (zh) | 弹性蛋白酶的全氟烷基酮抑制剂及其制备方法 | |
| CN1203089C (zh) | 新化合物 | |
| CN1205187C (zh) | 新的脒基衍生物及其作为凝血酶抑制剂的用途 | |
| CN1273128C (zh) | 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺 | |
| CN1129604C (zh) | 新的氨基酸衍生物及其作为凝血酶抑制剂的用途 | |
| CN1076199A (zh) | 新的肽衍生物 | |
| CN1228783A (zh) | 新的凝血酶抑制剂 | |
| CN1134148A (zh) | 抗血栓形成的脒基苯丙氨酸和脒基吡啶丙氨酸的衍生物 | |
| CN1351609A (zh) | 低分子量补体蛋白酶抑制剂 | |
| CN1016778B (zh) | 螺-取代的戊二酸单酰胺 | |
| HK1044936A1 (zh) | 凝血酶抑制剂 | |
| CN1064683A (zh) | 新的β-氨基-α羟基羧酸及其用途 | |
| CN1313863A (zh) | 尿激酶和血管形成的抑制剂 | |
| CN1228765A (zh) | 新脒基衍生物和它们作为凝血酶抑制剂的用途 | |
| HK1046289A1 (zh) | 凝血酶抑制剂的前体药物 | |
| CN1289341A (zh) | 凝血酶抑制剂 | |
| CN1047870A (zh) | 抑制肾素的肽类、它们的制备方法以及它们在医药方面的应用 | |
| CN1288467A (zh) | 具有生长激素释放性质的化合物 | |
| CN1349526A (zh) | 凝血酶抑制剂的前药 | |
| CN1747930A (zh) | 具有脯氨酰基寡肽酶抑制活性的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: AVECIA BIOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BASF AKTIENGESELLCHAFT Effective date: 20030403 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030403 Address after: Wiesbaden Applicant after: Ebert GmbH & Co. KG Address before: Ludwigshafen, Germany Applicant before: Basf AG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |